secwatch.observer — SEC 8-K summary
======================================

Issuer:     Indivior Pharmaceuticals, Inc. (INDV)
CIK:        0001625297
Form:       8-K
Filed at:   2025-06-02T23:59:59+00:00
Accession:  0001625297-25-000035
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Indivior to cancel London Stock Exchange secondary listing, maintain Nasdaq primary listing
--------------------------------------------------------------------------------

- London delisting effective July 25, 2025; last trading on LSE July 24, 2025.
- Over 80% of net revenue from US; 75% of trading volume on Nasdaq; over 70% of shareholders by value US-based.
- Nasdaq listing under INDV unaffected; direct holders and DTC broker/custodian holders unaffected.
- Holders of UK Depositary Interests and Corporate Sponsored Nominee facility advised to convert holdings for Nasdaq trading.
- UK Takeover Code remains applicable for 2 years after delisting; mandatory offer rules unchanged.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1625297/000162529725000035/0001625297-25-000035-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1625297/000162529725000035/a8-k05302025.htm
  HTML page:      https://secwatch.observer/filing/0001625297-25-000035

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer